# A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors

> **NCT04843033** · PHASE1 · UNKNOWN · sponsor: **Nanjing Sanhome Pharmaceutical, Co., Ltd.** · enrollment: 55 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** SH3809 tablet

## Key facts

- **NCT ID:** NCT04843033
- **Lead sponsor:** Nanjing Sanhome Pharmaceutical, Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-02
- **Primary completion:** 2023-10
- **Final completion:** 2023-12
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2021-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04843033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04843033, "A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04843033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*